公开(公告)号：US20180231570A1

公开(公告)日：2018-08-16

申请号：US15943104

申请日：2018-04-02

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Andrea Horsch ,  Birgit Klapperich ,  Dirk Block ,  Alfred Engel ,  Johann Karl ,  Rosemarie Kientsch-Engel ,  Ekaterina Manuilova ,  Christina Rabe ,  Sandra Rutz ,  Monika Soukupova ,  Ursula-Henrike Wienhues-Thelen ,  Peter Kastner ,  Edelgard Anna Kaiser

IPC: G01N33/68

CPC classification number: G01N33/6893 ,  G01N33/68 ,  G01N33/74 ,  G01N2333/47 ,  G01N2333/8139 ,  G01N2800/347 ,  G01N2800/50

Abstract: The present disclosure describes a method for predicting the risk of a patient to suffer from acute kidney injury (AKI) during or after a surgical procedure or after administration of a contrast medium. The method is based on the determination of the level of the biomarker IGFBP7 (Insulin-like Growth Factor Binding Protein 7) in a body fluid sample obtained from the patient prior to the surgical procedure or prior to the administration of a contrast medium. Further, the present disclosure describes a method for predicting the risk of a patient to suffer from acute kidney injury (AKI) based on the determination of the amount of the biomarker IGFBP7 (Insulin-like Growth Factor Binding Protein 7) and Cystatin C in a body fluid sample obtained from the patient. The present disclosure further encompasses kits and devices adapted to carry out the methods of the disclosed methods.

公开(公告)号：US20240352110A1

公开(公告)日：2024-10-24

申请号：US18745539

申请日：2024-06-17

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Alexander Jethwa ,  Tobias Oelschlaegel ,  Corinna Schindler ,  Monika Soukupova ,  Laura Stoeckl ,  Christina Zimmermann

IPC: C07K16/18 ,  G01N33/543 ,  G01N33/68

CPC classification number: C07K16/18 ,  G01N33/543 ,  G01N33/6896 ,  C07K2317/565 ,  G01N2333/4709 ,  G01N2470/04

Abstract: The present invention relates to a monoclonal antibody or an antigen-binding fragment thereof specifically binding to Aβ42 with advantageous features for Aβ42 detection in vitro using immunoassays. Also provided is a polynucleotide or a set of polynucleotides encoding the same and a vector comprising said polynucleotide(s). Further provided is a host cell comprising the polynucleotide(s) and a corresponding production process using this host cell. Also provided herein are uses and methods employing the monoclonal antibody or an antigen-binding fragment thereof specifically binding to Aβ42 as provided herein.

公开(公告)号：US20130288267A1

公开(公告)日：2013-10-31

申请号：US13923646

申请日：2013-06-21

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Michael Gerg ,  Dieter Heindl ,  Alfred Mertens ,  Christoph Rutz ,  Michael Schraeml ,  Monika Soukupova ,  Claudio Sustmann ,  Michael Tacke ,  Jan van Dieck

IPC: C07K16/46

CPC classification number: C07K16/468 ,  C07K16/18 ,  C07K16/2863 ,  C07K16/32 ,  C07K16/44 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/92 ,  C07K2317/94 ,  G01N33/6857

Abstract: A bivalent binding agent, capable of binding a polypeptide dimer, consisting of two monovalent binders linked to each other via a linker, the first monovalent binder binds an epitope of a first target polypeptide comprised in said dimer and the second monovalent binder binds to an epitope of a second target polypeptide comprised in said dimer. Each monovalent binder has a Kdiss in the range of 5×10−3/sec to 10−4/sec, and the bivalent binding agent has a Kdiss of 3×10−5/sec or less. Methods of making and using such bivalent binding agent in histological staining procedures are also disclosed.

Abstract translation: 能够结合多肽二聚体的二价结合剂，其由通过接头彼此连接的两个单价结合物组成，所述第一单价键合物结合包含在所述二聚体中的第一目标多肽的表位，并且所述第二单价键合物结合表位 的包含在所述二聚体中的第二目标多肽。 每个一价粘合剂的Kdiss在5×10-3 /秒至10-4 /秒的范围内，二价结合剂的Kdiss为3×10-5 /秒或更小。 还公开了在组织学染色方法中制备和使用这种二价结合剂的方法。

公开(公告)号：US10982007B2

公开(公告)日：2021-04-20

申请号：US15465439

申请日：2017-03-21

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Michael Gerg ,  Dieter Heindl ,  Christian Klein ,  Alfred Mertens ,  Volker Schmid ,  Michael Schraeml ,  Monika Soukupova ,  Michael Tacke

IPC: C07K16/46 ,  G01N33/531

Abstract: A bivalent binding agent having a first monovalent binder that binds to a polypeptide epitope of a target polypeptide, a second monovalent binder that binds to a posttranslational polypeptide modification on the target polypeptide and a linker. Further disclosed are methods for the detection of a posttranslationally modified target polypeptide, for making the disclosed bivalent binding agent, and for use of the disclosed bivalent binding agent in histological staining procedures.

公开(公告)号：US20170275380A1

公开(公告)日：2017-09-28

申请号：US15465379

申请日：2017-03-21

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Michael Gerg ,  Dieter Heindl ,  Alfred Mertens ,  Christoph Rutz ,  Michael Schraemi ,  Monika Soukupova ,  Claudio Sustmann ,  Michael Tacke ,  Jan van Dieck

IPC: C07K16/46 ,  C07K16/28 ,  C07K16/44 ,  G01N33/68 ,  C07K16/18 ,  C07K16/32

CPC classification number: C07K16/468 ,  C07K16/18 ,  C07K16/2863 ,  C07K16/32 ,  C07K16/44 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/92 ,  C07K2317/94 ,  G01N33/6857

Abstract: A bivalent binding agent, capable of binding a polypeptide dimer, consisting of two monovalent binders linked to each other via a linker, the first monovalent binder binds an epitope of a first target polypeptide comprised in said dimer and the second monovalent binder binds to an epitope of a second target polypeptide comprised in said dimer. Each monovalent binder has a Kdiss in the range of 5×10−3/sec to 10−4/sec, and the bivalent binding agent has a Kdiss of 3×10−5/sec or less. Methods of making and using such bivalent binding agent in histological staining procedures are also disclosed.

公开(公告)号：US11372000B2

公开(公告)日：2022-06-28

申请号：US16538886

申请日：2019-08-13

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Klaus Hallermayer ,  Monika Soukupova ,  Christina Porzig ,  Ulrike Kurtkaya ,  Leopold Von Proff ,  Sonja Fiesel ,  Marion Herrmann ,  Stefanie Kern

IPC: C07K16/26 ,  A61K39/395 ,  G01N33/68 ,  C07K14/575 ,  C07K14/58

Abstract: The present disclosure relates to an antibody that specifically binds a mutated NT-proBNP having i) a mutation substituting arginine at position 46 with histidine or ii) a mutation substituting glutamic acid at position 43 with aspartic acid. Moreover, the present disclosure relates to a mutated NT-proBNP or fragment thereof. Further, envisaged by the present disclosure are kits containing the antibody of the present disclosure, or the mutated NT-proBNP of the present disclosure. The present disclosure also concerns a method for diagnosing heart failure.

公开(公告)号：US20170275381A1

公开(公告)日：2017-09-28

申请号：US15465439

申请日：2017-03-21

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Michael Gerg ,  Dieter Heindl ,  Christian Klein ,  Alfred Mertens ,  Volker Schmid ,  Michael Schraemi ,  Monika Soukupova ,  Michael Tacke

IPC: C07K16/46 ,  G01N33/531

CPC classification number: C07K16/468 ,  G01N33/531

Abstract: A bivalent binding agent having a first monovalent binder that binds to a polypeptide epitope of a target polypeptide, a second monovalent binder that binds to a posttranslational polypeptide modification on the target polypeptide and a linker. Further disclosed are methods for the detection of a posttranslationally modified target polypeptide, for making the disclosed bivalent binding agent, and for use of the disclosed bivalent binding agent in histological staining procedures.

公开(公告)号：US20170096487A1

公开(公告)日：2017-04-06

申请号：US15083686

申请日：2016-03-29

Applicant: Roche Diagnostics Operations, Inc. ,  Ventana Medical Systems, Inc.

Inventor： Monika Soukupova ,  Michael Schraeml ,  Birgit Bossenmaier ,  Patrick C. Roche ,  Michael Gerg ,  Sebastian Dziadek

IPC: C07K16/28 ,  G01N33/574 ,  C07K16/30 ,  G01N33/74 ,  G01N1/30

CPC classification number: C07K16/2863 ,  C07K16/3023 ,  C07K16/3046 ,  C07K16/32 ,  C07K2317/33 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/92 ,  C07K2317/94 ,  G01N1/30 ,  G01N33/57492 ,  G01N33/74 ,  G01N2001/302 ,  G01N2333/71

Abstract: The present invention relates to isolated antibodies, or an antigen portions thereof, which bind to human HER3. The novel antibodies are of great utility since they allow for the sensitive and specific detection of human HER3. Detection of human HER3 is, e.g., possible in a tissue sample, even when such tissue sample is a formalin-fixed paraffin embedded tissue (FFPET) sample.

公开(公告)号：US20150355199A1

公开(公告)日：2015-12-10

申请号：US14835821

申请日：2015-08-26

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Alfred Engel ,  Andreas Gallusser ,  Johann Karl ,  Peter Kastner ,  Wolfgang Obermeier ,  Monika Soukupova

IPC: G01N33/68 ,  C07K16/18 ,  G01N33/543

CPC classification number: C07K16/18 ,  C07K14/472 ,  C07K2317/30 ,  C07K2317/33 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/92 ,  G01N33/54306 ,  G01N33/6893 ,  G01N33/6896 ,  G01N2800/28 ,  G01N2800/2814 ,  G01N2800/30 ,  G01N2800/52

Abstract: The present invention relates to an assay for specific detection of complement factor H-related protein 1 (CFHR1) in a sample from a subject, as well as kits and agents related thereto.

Abstract translation: 本发明涉及用于特异性检测来自受试者的样品中的补体因子H相关蛋白1（CFHR1）的测定，以及与其相关的试剂盒和试剂。